ArticleWorld journal of surgical oncology2025
Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study.
Junxiao Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.